SynthesisEndocrinology, diabetes & metabolism2022

Benefits and harms of sodium-glucose co-transporter-2 inhibitors (SGLT2-I) and renin-angiotensin-aldosterone system inhibitors (RAAS-I) versus SGLT2-Is alone in patients with type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials.

Samuel Seidu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.